Claims for Patent: 8,071,546

Summary for Patent: 8,071,546

Title:	Uses of pegylated albumin
Abstract:	The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.
Inventor(s):	Cabrales; Pedro (San Diego, CA), Tsai; Amy (San Diego, CA), Acharya; Seetharama A. (Cresskill, NJ), Manjula; Belur N. (Cresskill, NJ)
Assignee:	La Jolla Bioengineering Institute (La Jolla, CA) Albert Einstein College of Medicine of Yeshiva University (Bronx, NY)
Application Number:	11/921,689
Patent Claims:	1. A method of treating cardiac arrhythmia in a subject having cardiac arrhythmia which comprises administering to the subject an amount of a PEGylated albumin effective to treat cardiac arrhythmia in the subject. 2. The method of claim 1, wherein the cardiac arrhythmia is a ventricular arrhythmia. 3. The method of claim 1, wherein the cardiac arrhythmia is an atrial arrhythmia. 4. The method of claim 1, wherein the albumin is human serum albumin or bovine serum albumin. 5. The method of claim 1, wherein the concentration of PEGylated albumin is 1.5 g/dL-5.0 g/dL. 6. The method of claim 5, wherein the PEGylated albumin is administered at a dose of 16 to 30 ml/kg body weight/hr. 7. The method of claim 1, wherein the PEGylated albumin has a molecular weight of about 130 kDa. 8. The method of claim 1, wherein 6-18 PEG chains are conjugated to albumin. 9. The method of claim 1, wherein each PEG chain of the PEGylated albumin has a molecular weight of 200 daltons to 20,000 daltons. 10. The method of claim 9, wherein each PEG chain has a molecular weight of 3,000 to 5,000 daltons. 11. The method of claim 1, wherein the PEGylated albumin has a molecular radius of 8-9 nm. 12. The method of claim 1, wherein the PEGylated albumin has a colloid osmotic pressure of 37-40 mm Hg. 13. The method of claim 1, wherein the PEGylated albumin has a viscosity of 2.0 to 4.0 cP. 14. The method of claim 1, wherein a polyethylene glycol (PEG) used to make the PEGylated albumin is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG. 15. The method of claim 14, wherein the maleimide PEG is a maleimide phenyl PEG or a maleimide PEG comprising an alkyl linker. 16. The method of claim 1, wherein the PEG is attached to the albumin via a linker and/or an extension arm. 17. The method of claim 16, wherein the linker comprises an alkyl, aryl and/or heteroaryl group. 18. The method of claim 16, wherein the linker or extension arm comprises a .delta.-mercapto butyrimidyl chain or a .gamma.-mercapto propylamide chain. 19. The method of claim 1, wherein the PEGylated albumin comprises a polyethylene glycol (PEG) attached to a thiolated amino group of albumin, and wherein the amino group is thiolated using dithiobis(sulfosuccinimidyl propionate) (DTSSP) or dithiobis(succinimidyl propionate) (DTSP) or dithiobispropionimidate. 20. The method of claim 1, wherein PEGylation of albumin does not alter the surface charge of albumin. 21. The method of claim 1, wherein the subject is undergoing anaesthesia and surgery. 22. The method of claim 1, wherein the concentration of PEGylated albumin is 2.5 g/dL. 23. The method of claim 22, wherein the PEGylated albumin is administered at a dose of 24 ml/kg body weight/hr. 24. The method of claim 1, wherein 12 PEG chains are conjugated to albumin. 25. The method of claim 1, wherein each PEG chain of the PEGylated albumin has a molecular weight of 5,000 daltons. 26. The method of claim 1, wherein administration of PEGylated albumin decreases sinoatrial automaticity, partially normalizes ventricular contraction, and increases the duration of the cardiac monophasic action potential. 27. The method of claim 1, wherein the cardiac arrhythmia is induced by a drug or by nerve stimulation during surgery or is associated with cardiac disease, hypoxia, acidosis, hypercarbia or an electrolyte disturbance.

Details for Patent 8,071,546

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2025-06-10
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2025-06-10
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2025-06-10
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2025-06-10
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2025-06-10
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2025-06-10